SCHEMBL3004071

SCHEMBL3004071

CC(C)(C)c1ccc(S(=O)(=O)C2CCN(c3nc(-c4cccc(Br)c4)cs3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.47
RAB9A P51151 7/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 5/20 0.43
HSD17B10 Q99714 2/20 0.43
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
CDC25A P30304 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 4/20 0.42
AR P10275 1/20 0.42
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 3/20 0.39
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008228 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3021694 0.90 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3011967 0.90 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3017641 0.88 LMNA (0.55) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3012425 0.88 MAPT (0.54) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3000308 0.88 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3016185 0.87 RAB9A (0.49) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3017140 0.87 MAPT (0.59) SMN1; SMN2MAPTHSD17B10USP2RECQL
SCHEMBL3017544 0.87 MAPT (0.54) SMN1; SMN2RAB9ANPC1MAPTHSD17B10
SCHEMBL3011413 0.86 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.